Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by mercedesmanon Jun 30, 2022 10:27am
151 Views
Post# 34793630

RE:RE:500 million revenue for Qap's

RE:RE:500 million revenue for Qap'sAgree...but he also seems very open to the idea of being acquired...but acknowledges that there needs to be a "substantial premium"

I'm not expecting an offer yet, but I think the capacity ramp-up will make the Company that much more intriguing to buyers and Cameron likely knows this.

Just hoping we can get through the general market malaise without dropping too much more.  Once it's apparent that existing and new customers will be taking up all of the new-found capacity in QAPs especially, and still want more...I think the stock starts to move rapidly ...right about the time when M&A activity will start up again (likley 2023).  If not - a possible Nasdaq move in late 2023 or early 2024 will be the catalyst to properly monetize the investment.

MM
<< Previous
Bullboard Posts
Next >>